Context Therapeutics, Inc. CNTX 深 沪
已收盘 05-08 16:00:00 美东时间
2.38
+0.050
+2.15%
华盛通- 最 高2.40
- 今 开2.33
- 成交量 53.77万股
- 最 低 2.27
- 昨 收 2.33
- 总市值 2.19亿
- 52周最高 3.62
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 0.49
- 委 比 52.94%
- 总股本 9187.92万
- 历史最高 10.87
- 量 比 0.91
- 振 幅 5.58%
- 历史最低 0.47
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 80 percent decrease over losses of $(0.05) per share from
05-07 04:54
Context Therapeutics Receives FDA's Fast Track Designation For CTIM-76 To Treat Platinum-Resistant Ovarian Cancer
Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced that the U.S.
04-02 19:34
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7
Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight and raises the price target from $4 to $7.
03-24 20:59
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 34.62 percent.
03-24 04:20
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7
Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.
2025-12-22 20:25
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
2025-11-06 19:52
Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 9.89 percent. This is a 54.55 percent increase over losses of $(0.22) per share
2025-11-06 06:02
